Alvotech (ALVO) Accumulated Expenses (2021 - 2023)

Alvotech's (ALVO) quarterly Accumulated Expenses came in at $14.5 million in Q2 2023, down 22.44% on a QoQ basis from $18.7 million in Q4 2022.

Alvotech (ALVO) Accumulated Expenses (2021 - 2023) Analysis & Trends

Alvotech (ALVO) has 3 years of Accumulated Expenses data on file, last reported at $14.5 million in Q2 2023.

Quarterly Accumulated Expenses changed N/A year-over-year to $14.5 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $14.5 million (changed N/A YoY) and the FY2022 annual result came in at $18.7 million, up 391122.57% from the prior year.
Accumulated Expenses retreated to $14.5 million in Q2 2023, from $18.7 million in the prior quarter.
In the past five years, Accumulated Expenses ranged from a high of $18.7 million in Q4 2022 to a low of $4785.0 in Q4 2021.
A 3-year average of $11.1 million and a median of $14.5 million in 2023 frame the typical range for Accumulated Expenses.
The widest YoY moves for Accumulated Expenses: up 391122.57% in 2022, down 391122.57% in 2022.
Tracing ALVO's Accumulated Expenses over 3 years: stood at $4785.0 in 2021, then jumped by 391122.57% to $18.7 million in 2022, then fell by 22.44% to $14.5 million in 2023.
The last three Accumulated Expenses figures came in at $14.5 million (Q2 2023), $18.7 million (Q4 2022), and $4785.0 (Q4 2021), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Alvotech	1.26 Bn	1.26 Bn	5.09 Mn

Download Data